Dossier assessment
Elacestrant (breast cancer; = 1 prior therapy) – Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Elacestrant (breast cancer; = 1 prior therapy) – Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Elacestrant (breast cancer; = 1 prior therapy) – Benefit assessment according to §35a Social Code Book V
Dossier assessment
Postmenopausal women, and men, with oestrogen receptor positive, HER2-negative, locally advanced or metastatic breast cancer with an activating ESR1 mutation who have disease progression following at least one line of endocrine therapy including a CDK 4/6 inhibitor
- Postmenopausal women: added benefit not proven
- Men: added benefit not proven
Additional information
Federal Joint Committee (G-BA)
2024-05-02 A G-BA decision was published.
Project details
- Project no.
- A23-104
- Commission
- Commission awarded on 31.10.2023 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
- DOI
https://dx.doi.org/10.60584/A23-104_en